Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 12/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 10/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | LSS | P48449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7968426 | 0.86 | SLC6A4 (0.55) | SLC6A4DRD2HRH3KDM4ESLC6A2 | |
| SCHEMBL27749604 | 0.80 | DRD2 (0.50) | DRD2CYP2D6HTR1ACYP3A4 | |
| SCHEMBL10268348 | 0.79 | SLC6A4 (0.69) | SLC6A4DRD2HRH3KDM4ESLC6A2 | |
| Ammonia Solution, Strong SCHEMBL3406155 | 0.79 | DRD2 (0.49) | DRD2CYP2D6HTR1ACYP3A4 | |
| Hydrochloric Acid SCHEMBL27854009 | 0.78 | DRD2 (0.47) | DRD2HTR1A | |
| SCHEMBL13698231 | 0.76 | SLC6A4 (0.61) | SLC6A4DRD2HRH3KDM4ESLC6A2 | |
| SCHEMBL9205714 | 0.76 | DRD2 (0.57) | DRD2HTR1A | |
| SCHEMBL1342921 | 0.76 | DRD2 (0.57) | DRD2HTR1A | |
| SCHEMBL973130 | 0.76 | DRD2 (0.57) | DRD2HTR1A | |
| SCHEMBL1424708 | 0.76 | DRD2 (0.57) | DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144898-B2 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1242411-B1 | INDOLE DERIVATIVES FOR THE TREATMENT OF DEPRESSION AND ANXIETY | LILLY CO ELI (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006229-A1 | Indole derivatives for the treatment of depression and anxiety | IDO1, TPH1, IDO2 | SLC6A4 45/4885DRD2 41/4885HRH3 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.